{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:27:40Z","timestamp":1791613660357,"version":"4.3.4"},"reference-count":124,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chimeric antigen receptor T-cell (CAR-T) therapy has ushered in a new era for the treatment of multiple myeloma (MM). Numerous clinical studies, especially those involving B-cell maturation antigen (BCMA)-directed CAR-T, have shown remarkable efficacy in patients with relapsed or refractory multiple myeloma (R\/R MM). However, a considerable number of patients still experience disease recurrence or progression after BCMA CAR-T treatment, which is attributed to various factors, including antigen escape, CAR-T manufacturing factors, T cell exhaustion, inhibitory effects of tumor microenvironment and impact of prior treatments. The scarcity of effective treatment options following post-CAR-T disease recurrence, coupled with the lack of well-established salvage regimens, leaves patients who do relapse facing a bleak prognosis. In recent years, some academic institutions have achieved certain results in salvage treatments of patients with relapse after BCMA CAR-T treatment through secondary infusion of BCMA CAR-T, changing to non-BCMA-directed CAR-T, double-target CAR-T, bispecific antibodies or other novel therapies. This review summarizes the mechanisms of resistance or relapse after BCMA CAR-T administration and the available data on current salvage treatments, hoping to provide ideas for optimizing clinical salvage therapies.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1433774","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T04:35:17Z","timestamp":1729571717000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy"],"prefix":"10.3389","volume":"15","author":[{"given":"Bingjie","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gongzhizi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zujie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aili","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50129","article-title":"Biology and therapy of multiple myeloma","volume":"210","author":"Joshua","year":"2019","journal-title":"Med J Aust"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","article-title":"Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad306","article-title":"Perspectives on the treatment of multiple myeloma","volume":"29","author":"Rafae","year":"2024","journal-title":"Oncologist"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3176","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"BMJ"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.12.004","article-title":"Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma","volume":"39","author":"Uckun","year":"2018","journal-title":"EBioMedicine"},{"key":"B6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1146\/annurev-med-050522-033815","article-title":"New biological therapies for multiple myeloma","volume":"75","author":"Garfall","year":"2024","journal-title":"Annu Rev Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1158\/1078-0432.CCR-20-3600","article-title":"Facts and hopes in multiple myeloma immunotherapy","volume":"27","author":"Sperling","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112639","article-title":"CART-cell therapy: Recent advances and new evidence in multiple myeloma","volume":"13","author":"Martino","year":"2021","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","article-title":"Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial","volume":"17","author":"Xu","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33002","article-title":"B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives","volume":"147","author":"Sellner","year":"2020","journal-title":"Int J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2021.06.015","article-title":"Endogenous soluble receptors sBCMA and sTACI: Biomarker, immunoregulator and hurdle for therapy in multiple myeloma","volume":"71","author":"Meinl","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.266841","article-title":"BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice","volume":"108","author":"Zhou","year":"2022","journal-title":"Haematologica"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"[amp]]gamma;-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/biom12091303","article-title":"Co-stimulatory receptor signaling in CAR-T cells","volume":"12","author":"Honikel","year":"2022","journal-title":"Biomolecules"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq3016","article-title":"Metabolic challenges and interventions in CAR T cell therapy","volume":"8","author":"Peng","year":"2023","journal-title":"Sci Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.coi.2021.02.010","article-title":"Mechanisms of response and resistance to CAR T cell therapies","volume":"69","author":"Berger","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.539654","article-title":"4-1BB signaling boosts the anti-tumor activity of CD28-incorporated 2nd generation chimeric antigen receptor-modified T Cells","volume":"11","author":"Dai","year":"2020","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910828","article-title":"Improving CAR T-cell persistence","volume":"22","author":"Pietrobon","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.886546","article-title":"Immunogenicity of CAR-T Cell therapeutics: Evidence, mechanism and mitigation","volume":"13","author":"Khan","year":"2022","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current state and next-generation CAR-T cells in multiple myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2021.112971","article-title":"Resistance and recurrence of Malignancies after CAR-T cell therapy","volume":"410","author":"Zeng","year":"2022","journal-title":"Exp Cell Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01301-8","article-title":"Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.12.018","article-title":"Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain","volume":"32","author":"Mikkilineni","year":"2024","journal-title":"Mol Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139802","article-title":"Results from lummicar-2: A phase 1b\/2 study of fully human B-cell maturation antigen-specific CAR T cells (CT053) in patients with relapsed and\/or refractory multiple myeloma","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6616391","article-title":"T Cell Exhaustion and CAR-T immunotherapy in hematological Malignancies","volume":"2021","author":"Tang","year":"2021","journal-title":"BioMed Res Int"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012416","article-title":"CD4+ CAR-T cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR-T cell therapy","volume":"8","author":"Ledergor","year":"2024","journal-title":"Blood Adv"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01719","article-title":"T cell dysfunction in cancer immunity and immunotherapy","volume":"10","author":"Xia","year":"2019","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of resistance to chimeric antigen receptor-T cells in haematological Malignancies","volume":"22","author":"Ruella","year":"2023","journal-title":"Nat Rev Drug Discovery"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","article-title":"Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells","volume":"56","author":"Agarwal","year":"2023","journal-title":"Immunity"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)\u2013modified T cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008429","article-title":"PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion","volume":"12","author":"Ouyang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040988","article-title":"Challenges for immunotherapy in multiple myeloma: Bone marrow microenvironment-mediated immune suppression and immune resistance","volume":"12","author":"Holthof","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities","volume":"25","author":"Kankeu Fonkoua","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005020","article-title":"Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma","volume":"5","author":"Kennedy","year":"2021","journal-title":"Blood Adv"},{"key":"B50","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40164-023-00402-5","article-title":"Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing","volume":"12","author":"Li","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012811","article-title":"Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma","volume":"139","author":"Sakemura","year":"2022","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21771","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2020-134369","article-title":"Effects of prior alkylating therapies on preinfusion patient characteristics and starting material for CAR T cell product manufacturing in late-line multiple myeloma","volume":"136","author":"Rytlewski","year":"2020","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18831","article-title":"Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan","volume":"202","author":"Jo","year":"2023","journal-title":"Br J Haematology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181762","article-title":"Real world outcomes with idecabtagene vicleucel (Ide-cel) CAR-T cell therapy for relapsed\/refractory multiple myeloma","volume":"142","author":"Sidana","year":"2023","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6619","article-title":"Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma","volume":"12","author":"Bisht","year":"2023","journal-title":"Cancer Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26745","article-title":"Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed\/refractory multiple myeloma","volume":"97","author":"Chen","year":"2022","journal-title":"Am J Hematol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2023","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematology"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01824","article-title":"Anti\u2013G Protein\u2013Coupled Receptor, Class C Group 5 Member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: A single-arm, Phase II trial","volume":"41","author":"Xia","year":"2023","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2023-179147","article-title":"Safety and efficacy of GPRC5D CAR T cell therapy in relapsed\/refractory multiple myeloma patients","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02065-x","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","volume":"38","author":"Li","year":"2024","journal-title":"Leukemia"},{"key":"B68","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","article-title":"Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat Commun"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): Updated results from an ongoing Phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162253","article-title":"Final results from the first-in-human Phase 1\/2 study of Modakafusp Alfa, an immune-targeting attenuated cytokine, in patients (Pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"140","author":"Vogl","year":"2022","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1182\/blood-2023-173202","article-title":"A phase 2 study of nivolumab for relapsed\/refractory multiple myeloma or Non-Hodgkin Lymphoma following CAR-T therapy","volume":"142","author":"Banerjee","year":"2023","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16550","article-title":"Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy","volume":"189","author":"Chari","year":"2020","journal-title":"Br J Haematol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2021.06.010","article-title":"Humanized BCMA CAR- T cell salvage therapy in two refractory multiple myeloma patients who progressed after their murine BCMA CAR-T cell therapy","volume":"42","author":"Cui","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-023-00712-0","article-title":"An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737140.2024.2343114","article-title":"Targeting GPRC5D in multiple myeloma","author":"Elemian","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003342","article-title":"A T-cell\u2013redirecting bispecific G-protein\u2013coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41408-023-00966-9","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"14","author":"Rodriguez-Otero","year":"2024","journal-title":"Blood Cancer J"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181857","article-title":"BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): Updated results from a Phase 1 study","volume":"142","author":"Bal","year":"2023","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.108007","article-title":"Chimeric Antigen Receptor (CAR) T-cell therapy for multiple myeloma","volume":"232","author":"Choi","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13840","article-title":"Treatment horizon in multiple myeloma","volume":"109","author":"Soekojo","year":"2022","journal-title":"Eur J Haematol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042921-024719","article-title":"Multispecific CAR T Cells deprive lymphomas of escape via antigen loss","volume":"74","author":"Furqan","year":"2023","journal-title":"Annu Rev Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30090573","article-title":"SLAMF7 as a promising immunotherapeutic target in multiple myeloma treatments","volume":"30","author":"Chu","year":"2023","journal-title":"Curr Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3064","article-title":"Characterization of clonogenic multiple myeloma cells","volume":"103","author":"Matsui","year":"2004","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.211","article-title":"Differentiation stage of myeloma plasma cells: biological and clinical significance","volume":"31","author":"Paiva","year":"2017","journal-title":"Leukemia"},{"key":"B90","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1038\/s41467-019-10948-w","article-title":"Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T","volume":"10","author":"Nerreter","year":"2019","journal-title":"Nat Commun"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1032775","article-title":"Bispecific antibodies in multiple myeloma treatment: A journey in progress","volume":"12","author":"Cho","year":"2022","journal-title":"Front Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0028","article-title":"Bispecific antibodies in multiple myeloma: present and future","volume":"2","author":"Lancman","year":"2021","journal-title":"Blood Cancer Discovery"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8013","article-title":"Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents","volume":"40","author":"Touzeau","year":"2022","journal-title":"JCO"},{"key":"B94","doi-asserted-by":"publisher","first-page":"308.e1","DOI":"10.1016\/j.jtct.2023.12.016","article-title":"Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: A real-world experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283931","article-title":"Talquetamab in multiple myeloma","volume":"109","author":"Liu","year":"2023","journal-title":"Haematologica"},{"key":"B96","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1182\/blood-2023-187242","article-title":"Updated results of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma with prior exposure to T-cell redirecting therapies: Results of the Phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Jakubowiak","year":"2023","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32065","article-title":"Daratumumab in multiple myeloma","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967680.90062.ca","article-title":"S192: Talquetamab (Tal) + daratumumab (Dara) in patients (Pts) with relapsed\/refractory multiple myeloma (RRMM): Update TRIMM-2 results","volume":"7","author":"Bahlis","year":"2023","journal-title":"Hemasphere"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720930629","article-title":"Selinexor in relapsed\/refractory multiple myeloma","volume":"11","author":"Richter","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000866","article-title":"Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas","volume":"34","author":"Goldsmith","year":"2022","journal-title":"Curr Opin Oncol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.1182\/blood-2023-173730","article-title":"Preliminary results of the Oral CD73 inhibitor, Oric-533, in relapsed\/refractory multiple myeloma (RRMM)","volume":"142","author":"Rodriguez","year":"2023","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109933","article-title":"Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy","volume":"189","author":"Ababneh","year":"2023","journal-title":"Radiother Oncol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41408-022-00725-2","article-title":"Iopofosine I-131 treatment in late-line patients with relapsed\/refractory multiple myeloma post anti-BCMA immunotherapy","volume":"12","author":"Longcor","year":"2022","journal-title":"Blood Cancer J"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.649824","article-title":"Successful treatment of relapsed\/refractory extramedullary multiple myeloma with anti-BCMA CAR-T cell therapy followed by haploidentical hematopoietic stem cell transplantation: A case report and a review of the contemporary literature","volume":"8","author":"Qian","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B106","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-022-01330-3","article-title":"Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation","volume":"15","author":"Elnaggar","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-160401","article-title":"Clinical outcomes and salvage therapies in patients with relapsed\/refractory multiple myeloma following progression on BCMA-targeted CAR-T therapy","volume":"140","author":"Reyes","year":"2022","journal-title":"Blood"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012066","article-title":"Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma","volume":"8","author":"Reyes","year":"2024","journal-title":"Blood Adv"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012773","article-title":"A research center\u2019s experience of T-cell redirecting therapies in triple-class refractory multiple myeloma","volume":"8","author":"Puertas","year":"2024","journal-title":"Blood Adv"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19340","article-title":"Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy: A retrospective analysis of LEGEND-2","volume":"204","author":"Liu","year":"2024","journal-title":"Br J Haematol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.1038\/s41467-023-43416-7","article-title":"Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma","volume":"14","author":"Larson","year":"2023","journal-title":"Nat Commun"},{"key":"B112","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41467-024-44873-4","article-title":"Bispecific BCMA\/CD24 CAR-T cells control multiple myeloma growth","volume":"15","author":"Sun","year":"2024","journal-title":"Nat Commun"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape\u2013driven relapse in multiple myeloma","volume":"1","author":"Fern\u00e1ndez de Larrea","year":"2020","journal-title":"Blood Cancer Discovery"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-0839","article-title":"Dual chimeric antigen receptor T cells targeting CD38 and SLAMF7 with independent signaling demonstrate preclinical efficacy and safety in multiple myeloma","volume":"12","author":"Roders","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1959102","article-title":"Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma","volume":"10","author":"Feng","year":"2021","journal-title":"Oncoimmunology"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5818","article-title":"A second-generation CD38-CAR-T cell for the treatment of multiple myeloma","volume":"12","author":"Li","year":"2023","journal-title":"Cancer Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase 1 trial of autologous CAR T Cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B118","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1038\/s41467-023-39395-4","article-title":"Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat Commun"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting Malignancy-associated \u03ba light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Invest"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236136","article-title":"Promising antigens for the new frontier of targeted immunotherapy in multiple myeloma","volume":"13","author":"Cho","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B121","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00262-021-02959-8","article-title":"Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed\/refractory multiple myeloma: a case report and revies of the literature","volume":"71","author":"Zhao","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1097\/BS9.0000000000000184","article-title":"Pomalidomide improves the effectiveness of CAR-T treatment in the relapsed and refractory multiple myeloma or B-cell leukemia\/lymphoma with extramedullary disease","volume":"6","author":"Zhao","year":"2024","journal-title":"Blood Sci"},{"key":"B123","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1182\/blood-2023-181573","article-title":"BCMA CAR-T-cell therapy in combination with long-term pomalidomide is a safe and effective treatment for relapsed\/refractory multiple myeloma","volume":"142","author":"Yan","year":"2023","journal-title":"Blood"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19439","article-title":"Sequence not salvage","volume":"204","author":"Sborov","year":"2024","journal-title":"Br J Haematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1433774\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T04:35:20Z","timestamp":1729571720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1433774\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":124,"alternative-id":["10.3389\/fimmu.2024.1433774"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1433774","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]},"article-number":"1433774"}}